Considerations in the Choice of an Antiepileptic Drug in the Treatment of Epilepsy

 

 Buy Article Permissions and Reprints

ABSTRACT

The advent of multiple new antiepileptic drugs (AEDs) in the past 15 years has provided new options for clinicians treating patients with epilepsy, but has also created a need for guidelines in AED use. For selection of the most appropriate AED, the neurologist must know the pharmacological properties of the AEDs and has to balance their benefits and potential risks for the individual patient. A key consideration in AED selection is spectrum of efficacy for seizure types and epileptic syndrome. Other factors in AED selection include safety and tolerability, ease of use and titration rate, potential interactions, and efficacy in coexisting nonepileptic conditions. Comorbid conditions may favor or exclude the use of certain AEDs in a particular patient. Special considerations apply in specific epilepsy populations, such as women of childbearing age, children, and the elderly. This article analyzes the various factors involved in choosing an AED.

REFERENCES

• 1 [No authors listed] . Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy.  Epilepsia. 1981;  22 489-501
  CrossrefPubMedGoogle Scholar
• 2 French J A, Kanner A M, Bautista J et al.. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.  Neurology. 2004;  62 1252-1260
  PubMedGoogle Scholar
• 3 Brodie M J, Chadwick D W, Anhut H et al.. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.  Epilepsia. 2002;  43 993-1000
  CrossrefPubMedGoogle Scholar
• 4 Chadwick D W, Anhut H, Greiner M J et al.. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.  Neurology. 1998;  51 1282-1288
  CrossrefPubMedGoogle Scholar
• 5 Brodie M J, Richens A, Yuen A W. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group.  Lancet. 1995;  345 476-479
  CrossrefPubMedGoogle Scholar
• 6 Brodie M J, Overstall P W, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group.  Epilepsy Res. 1999;  37 81-87
  CrossrefPubMedGoogle Scholar
• 7 Saetre E, Perucca E, Isojarvi J, Gjerstad L. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly.  Epilepsia. 2007;  48 1292-1302
  CrossrefPubMedGoogle Scholar
• 8 Rowan A J, Ramsay R E, Collins J F et al.. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.  Neurology. 2005;  64 1868-1873
  CrossrefPubMedGoogle Scholar
• 9 Brodie M J, Perucca E, Ryvlin P, Ben-Menachem E, Meencke H J. Levetiracetam Monotherapy Study Group . Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.  Neurology. 2007;  68 402-408
  CrossrefPubMedGoogle Scholar
• 10 Mattson R H, Cramer J A, Collins J F et al.. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.  N Engl J Med. 1985;  313 145-151
  CrossrefPubMedGoogle Scholar
• 11 Mattson R H, Cramer J A, Collins J F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.  N Engl J Med. 1992;  327 765-771
  PubMedGoogle Scholar
• 12 Isojarvi J I, Laatikainen T J, Pakarinen A J, Juntunen K T, Myllyla V V. Menstrual disorders in women with epilepsy receiving carbamazepine.  Epilepsia. 1995;  36 676-681
  PubMedGoogle Scholar
• 13 Isojarvi J I, Repo M, Pakarinen A J, Lukkarinen O, Myllyla V V. Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy.  Epilepsia. 1995;  36 366-370
  CrossrefPubMedGoogle Scholar
• 14 Rattya J, Turkka J, Pakarinen A J et al.. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy.  Neurology. 2001;  56 31-36
  CrossrefPubMedGoogle Scholar
• 15 Isojarvi J I, Pakarinen A J, Rautio A, Pelkonen O, Myllyla V V. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine.  Eur J Clin Pharmacol. 1995;  47 461-464
  PubMedGoogle Scholar
• 16 Bill P A, Vigonius U, Pohlmann H et al.. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy.  Epilepsy Res. 1997;  27 195-204
  CrossrefPubMedGoogle Scholar
• 17 Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy.  Epilepsy Res. 1989;  3 70-76
  CrossrefPubMedGoogle Scholar
• 18 Guerreiro M M, Vigonius U, Pohlmann H et al.. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy.  Epilepsy Res. 1997;  27 205-213
  CrossrefPubMedGoogle Scholar
• 19 Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density.  Pediatr Neurol. 2006;  35 177-181
  CrossrefPubMedGoogle Scholar
• 20 Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.  Epilepsia. 2006;  47 510-515
  CrossrefPubMedGoogle Scholar
• 21 Isojarvi J I, Huuskonen U E, Pakarinen A J, Vuolteenaho O, Myllyla V V. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine.  Epilepsia. 2001;  42 741-745
  CrossrefPubMedGoogle Scholar
• 22 Dong X, Leppik I E, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine.  Neurology. 2005;  65 1976-1978
  CrossrefPubMedGoogle Scholar
• 23 Marson A G, Al-Kharusi A M, Alwaidh M et al.. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.  Lancet. 2007;  369 1000-1015
  CrossrefPubMedGoogle Scholar
• 24 Gillham R, Kane K, Bryant-Comstock L, Brodie M J. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure.  Seizure. 2000;  9 375-379
  CrossrefPubMedGoogle Scholar
• 25 Meador K J, Loring D W, Ray P G et al.. Differential cognitive and behavioral effects of carbamazepine and lamotrigine.  Neurology. 2001;  56 1177-1182
  PubMedGoogle Scholar
• 26 Sheth R D, Hermann B P. Bone mineral density with lamotrigine monotherapy for epilepsy.  Pediatr Neurol. 2007;  37 250-254
  CrossrefPubMedGoogle Scholar
• 27 Pack A M, Morrell M J, Marcus R et al.. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy.  Ann Neurol. 2005;  57 252-257
  CrossrefPubMedGoogle Scholar
• 28 Karceski S, Morrell M J, Carpenter D. Treatment of epilepsy in adults: expert opinion. 2005.  Epilepsy Behav. 2005;  7(suppl 1) S1-S64 , quiz S65–67
  PubMedGoogle Scholar
• 29 Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?.  Neurology. 2000;  55 1106-1109
  CrossrefPubMedGoogle Scholar
• 30 Yang M T, Lee W T, Chu L W, Shen Y Z. Anti-epileptic drugs-induced de novo absence seizures.  Brain Dev. 2003;  25 51-56
  CrossrefPubMedGoogle Scholar
• 31 Gelisse P, Genton P, Kuate C et al.. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies.  Epilepsia. 2004;  45 1282-1286
  CrossrefPubMedGoogle Scholar
• 32 Kaddurah A K, Holmes G L. Possible precipitation of myoclonic seizures with oxcarbazepine.  Epilepsy Behav. 2006;  8 289-293
  CrossrefPubMedGoogle Scholar
• 33 Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures.  Epilepsia. 1998;  39 5-17
  CrossrefPubMedGoogle Scholar
• 34 Meador K J, Baker G A, Finnell R H et al.. In utero antiepileptic drug exposure: fetal death and malformations.  Neurology. 2006;  67 407-412
  CrossrefPubMedGoogle Scholar
• 35 Marson A G, Al-Kharusi A M, Alwaidh M et al.. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.  Lancet. 2007;  369 1016-1026
  CrossrefPubMedGoogle Scholar
• 36 Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study.  Epilepsia. 2004;  45 1049-1053
  CrossrefPubMedGoogle Scholar
• 37 Buoni S, Grosso S, Fois A. Lamotrigine in typical absence epilepsy.  Brain Dev. 1999;  21 303-306
  CrossrefPubMedGoogle Scholar
• 38 Frank L M, Enlow T, Holmes G L et al.. Lamictal (lamotrigine) monotherapy for typical absence seizures in children.  Epilepsia. 1999;  40 973-979
  PubMedGoogle Scholar
• 39 Cavitt J, Privitera M. Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence.  Arch Neurol. 2004;  61 1604-1607
  CrossrefPubMedGoogle Scholar
• 40 Cross J H. Topiramate monotherapy for childhood absence seizures: an open label pilot study.  Seizure. 2002;  11 406-410
  CrossrefPubMedGoogle Scholar
• 41 Wilfong A, Schultz R. Zonisamide for absence seizures.  Epilepsy Res. 2005;  64(1–2) 31-34
  CrossrefPubMedGoogle Scholar
• 42 Calleja S, Salas-Puig J, Ribacoba R, Lahoz C H. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate.  Seizure. 2001;  10 424-427
  PubMedGoogle Scholar
• 43 Obeid T, Panayiotopoulos C P. Clonazepam in juvenile myoclonic epilepsy.  Epilepsia. 1989;  30 603-606
  CrossrefPubMedGoogle Scholar
• 44 Andermann E, Andermann F, Meyvisch P, Vandendriessche A, Schiemann Delgado J. Seizure control with levetiracetam in juvenile myoclonic epilepsies.  Epilepsia. 2005;  46(suppl 8) 205
  CrossrefPubMedGoogle Scholar
• 45 Krauss G L, Betts T, Abou-Khalil B et al.. Levetiracetam treatment of idiopathic generalised epilepsy.  Seizure. 2003;  12 617-620
  CrossrefPubMedGoogle Scholar
• 46 Sharpe D V, Patel A D, Abou-Khalil B, Fenichel G M. Levetiracetam monotherapy in juvenile myoclonic epilepsy.  Seizure. 2008;  17 64-68
  CrossrefPubMedGoogle Scholar
• 47 Prasad A, Kuzniecky R I, Knowlton R C et al.. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy.  Arch Neurol. 2003;  60 1100-1105
  CrossrefPubMedGoogle Scholar
• 48 Kothare S V, Valencia I, Khurana D S et al.. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.  Epileptic Disord. 2004;  6 267-270
  PubMedGoogle Scholar
• 49 Biraben A, Allain H, Scarabin J M, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine.  Neurology. 2000;  55 1758
  PubMedGoogle Scholar
• 50 Carrazana E J, Wheeler S D. Exacerbation of juvenile myoclonic epilepsy with lamotrigine.  Neurology. 2001;  56 1424-1425
  PubMedGoogle Scholar
• 51 Beghi E, Gatti G, Tonini C et al.. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial.  Epilepsy Res. 2003;  57 1-13
  CrossrefPubMedGoogle Scholar
• 52 Kwan P, Brodie M J. Epilepsy after the first drug fails: substitution or add-on?.  Seizure. 2000;  9 464-468
  CrossrefPubMedGoogle Scholar
• 53 Albani F, Grassi B, Ferrara R, Turrini R, Baruzzi A. Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch.  Seizure. 2004;  13 254-263
  CrossrefPubMedGoogle Scholar
• 54 Kwan P, Brodie M J. Early identification of refractory epilepsy.  N Engl J Med. 2000;  342 314-319
  CrossrefPubMedGoogle Scholar
• 55 Beydoun A, Fischer J, Labar D R et al.. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83.  Neurology. 1997;  49 746-752
  PubMedGoogle Scholar
• 56 Besag F M, Berry D J, Pool F, Newbery J E, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?.  Epilepsia. 1998;  39 183-187
  CrossrefPubMedGoogle Scholar
• 57 Kwan P, Brodie M J. Combination therapy in epilepsy: when and what to use.  Drugs. 2006;  66 1817-1829
  CrossrefPubMedGoogle Scholar
• 58 Brodie M J, Yuen A W. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group.  Epilepsy Res. 1997;  26 423-432
  CrossrefPubMedGoogle Scholar
• 59 Kinirons P, McCarthy M, Doherty C P, Delanty N. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam.  Seizure. 2006;  15 387-392
  CrossrefPubMedGoogle Scholar
• 60 French J A, Kanner A M, Bautista J et al.. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.  Neurology. 2004;  62 1261-1273
  CrossrefPubMedGoogle Scholar
• 61 Marson A G, Kadir Z A, Hutton J L, Chadwick D W. The new antiepileptic drugs: a systematic review of their efficacy and tolerability.  Epilepsia. 1997;  38 859-880
  CrossrefPubMedGoogle Scholar
• 62 Peters J M, Camfield C S, Camfield P R. Population study of benign rolandic epilepsy: is treatment needed?.  Neurology. 2001;  57 537-539
  CrossrefPubMedGoogle Scholar
• 63 Glauser T, Ben-Menachem E, Bourgeois B et al.. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.  Epilepsia. 2006;  47 1094-1120
  CrossrefPubMedGoogle Scholar
• 64 Kang H C, Eun B L, Wu Lee C et al.. The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy.  Epilepsia. 2007;  48 1716-1723
  CrossrefPubMedGoogle Scholar
• 65 Verrotti A, Coppola G, Manco R et al.. Levetiracetam monotherapy for children and adolescents with benign rolandic seizures.  Seizure. 2007;  16 271-275
  CrossrefPubMedGoogle Scholar
• 66 Coppola G, Franzoni E, Verrotti A et al.. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial.  Brain Dev. 2007;  29 281-284
  CrossrefPubMedGoogle Scholar
• 67 Tzitiridou M, Panou T, Ramantani G et al.. Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemporal spikes: a clinical and cognitive evaluation.  Epilepsy Behav. 2005;  7 458-467
  CrossrefPubMedGoogle Scholar
• 68 Motte J, Trevathan E, Arvidsson J F et al.. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.  N Engl J Med. 1997;  337 1807-1812
  CrossrefPubMedGoogle Scholar
• 69 Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome.  N Engl J Med. 1993;  328 29-33
  CrossrefPubMedGoogle Scholar
• 70 Sachdeo R C, Glauser T A, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.  Neurology. 1999;  52 1882-1887
  PubMedGoogle Scholar
• 71 Biton V, Bourgeois B F. Topiramate in patients with juvenile myoclonic epilepsy.  Arch Neurol. 2005;  62 1705-1708
  CrossrefPubMedGoogle Scholar
• 72 Nicolson A, Appleton R E, Chadwick D W, Smith D F. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies.  J Neurol Neurosurg Psychiatry. 2004;  75 75-79
  PubMedGoogle Scholar
• 73 Pellock J M, Brodie M J. Felbamate: 1997 update.  Epilepsia. 1997;  38 1261-1264
  CrossrefPubMedGoogle Scholar
• 74 Dreifuss F E, Santilli N, Langer D H et al.. Valproic acid hepatic fatalities: a retrospective review.  Neurology. 1987;  37 379-385
  CrossrefPubMedGoogle Scholar
• 75 White J R, Walczak T S, Leppik I E et al.. Discontinuation of levetiracetam because of behavioral side effects: a case-control study.  Neurology. 2003;  61 1218-1221
  CrossrefPubMedGoogle Scholar
• 76 Blum D, Meador K, Biton V et al.. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy.  Neurology. 2006;  67 400-406
  CrossrefPubMedGoogle Scholar
• 77 Biton V. Weight change and antiepileptic drugs: health issues and criteria for appropriate selection of an antiepileptic agent.  Neurologist. 2006;  12 163-167
  CrossrefPubMedGoogle Scholar
• 78 Bryant III A E, Dreifuss F E. Valproic acid hepatic fatalities: III. US experience since 1986.  Neurology. 1996;  46 465-469
  PubMedGoogle Scholar
• 79 Nadkarni S, LaJoie J, Devinsky O. Current treatments of epilepsy.  Neurology. 2005;  64(suppl 3) S2-S11
  CrossrefPubMedGoogle Scholar
• 80 Lofgren E, Mikkonen K, Tolonen U et al.. Reproductive endocrine function in women with epilepsy: the role of epilepsy type and medication.  Epilepsy Behav. 2007;  10 77-83
  CrossrefPubMedGoogle Scholar
• 81 Isojarvi J I, Rattya J, Myllyla V V et al.. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.  Ann Neurol. 1998;  43 446-451
  CrossrefPubMedGoogle Scholar
• 82 Wyszynski D F, Nambisan M, Surve T et al.. Increased rate of major malformations in offspring exposed to valproate during pregnancy.  Neurology. 2005;  64 961-965
  CrossrefPubMedGoogle Scholar
• 83 Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study.  Acta Paediatr. 2004;  93 174-176
  CrossrefPubMedGoogle Scholar
• 84 Viinikainen K, Eriksson K, Monkkonen A et al.. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children.  Epilepsy Behav. 2006;  9 636-640
  CrossrefPubMedGoogle Scholar
• 85 Vajda F J, Eadie M J. Maternal valproate dosage and foetal malformations.  Acta Neurol Scand. 2005;  112 137-143
  CrossrefPubMedGoogle Scholar
• 86 Morrow J, Russell A, Guthrie E et al.. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.  J Neurol Neurosurg Psychiatry. 2006;  77 193-198
  CrossrefPubMedGoogle Scholar
• 87 Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring.  Neurology. 2005;  64 1874-1878
  CrossrefPubMedGoogle Scholar
• 88 Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry.  Epilepsy Behav. 2003;  4 310-317
  CrossrefPubMedGoogle Scholar
• 89 Hunt S, Craig J, Russell A et al.. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.  Neurology. 2006;  67 1876-1879
  CrossrefPubMedGoogle Scholar
• 90 Hauser W A, Annegers J F, Kurland L T. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984.  Epilepsia. 1993;  34 453-468
  CrossrefPubMedGoogle Scholar
• 91 Perucca E, Berlowitz D, Birnbaum A et al.. Pharmacological and clinical aspects of antiepileptic drug use in the elderly.  Epilepsy Res. 2006;  68(S1) S49-S63
  CrossrefPubMedGoogle Scholar
• 92 Armon C, Shin C, Miller P et al.. Reversible parkinsonism and cognitive impairment with chronic valproate use.  Neurology. 1996;  47 626-635
  CrossrefPubMedGoogle Scholar
• 93 Ferrendelli J A, French J, Leppik I et al.. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial.  Epilepsy Behav. 2003;  4 702-709
  CrossrefPubMedGoogle Scholar
• 94 Groselj J, Guerrini R, Van Oene J et al.. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy.  Acta Neurol Scand. 2005;  112 144-150
  CrossrefPubMedGoogle Scholar

Bassel W Abou-KhalilM.D. 

Director, Epilepsy Program, Vanderbilt University

A-0118 MCN, Nashville, TN 37232-2551

Email: bassel.abou-khalil@vanderbilt.edu